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We described angiotensin-I-converting enzyme (ACE) isoforms with molecular masses of 190, 90, and 65 kDa in the urine of
normotensive offspring of hypertensive subjects. Since they did not appear in equal amounts, we suggested that 90 kDa ACE
might be a marker for hypertension. We evaluated the endothelial response in normotensive offspring with or without family
history of hypertension and its association with the 90 kDa ACE in urine. Thirty-five normotensive subjects with a known family
history of hypertension and 20 subjects without a family history of hypertension, matched for age, sex, body weight, and blood
pressure, were included in the study. Endothelial function was assessed by ultrasound and a sample of urine was collected for
determination of ACE isoforms. In the presence of a family history of hypertension and detection of 90 kDa ACE, we noted a
maximal flow mediated dilation of 12.1 ± 5.0 vs 16.1 ± 6.0% in those without a previous history of hypertension and lacking urinary
90 kDa ACE (P < 0.05). In subjects with a family history of hypertension and presenting 90 kDa ACE, there were lower levels of
HDL-cholesterol (P < 0.05) and higher levels of triglycerides (P < 0.05). Subjects with 90 kDa ACE irrespective of hypertensive
history presented a trend for higher levels of triglycerides and HDL-cholesterol (P = 0.06) compared to subjects without 90 kDa
ACE. Our data suggest that the 90 kDa ACE may be a marker for hypertension which may be related to the development of early
atherosclerotic changes.
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Introduction
The term endothelial dysfunction is used to define early
changes in endothelial function in different arterial sites in
humans, such as coronary, renal and peripheral circula-
tion (1). Endothelial cells have important properties, such
as providing a protective barrier between tissues and
circulating blood, functioning as a selective filter to facili-
tate the transport of macromolecules and blood gases
between tissues and blood and also releasing vasoactive
substances such as nitric oxide (NO), endothelium-de-
rived relaxing factors, angiotensin II, endothelin, among
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others (2-5). A disruption in the balance of these vasoac-
tive substances leads to vasospasm, vasoconstriction,
thrombogenesis, and abnormal vascular proliferation. Spe-
cifically, an impairment is associated with an increase in
NO production or a degradation caused mainly by endo-
thelial cell lesions and the increased production of free
radicals (reactive superoxide species) (6,7).
Zizek et al. (8) reported that vasodilator response of the
brachial artery was blunted during reactive hyperemia in
normotensive offspring of subjects with essential hyper-
tension (EH) compared to controls. They also found that
offspring of subjects with EH showed increased blood
pressure levels although within the normal range (8). Sev-
eral studies developed in our laboratory (9-11) have shown
that normotensive subjects with no family history of EH
consistently present urinary angiotensin-I-converting en-
zyme (ACE) isoforms with molecular masses of 190 and 65
kDa, which differ from those presented by normotensive
subjects with a positive history of EH (190, 90, and 65 kDa)
and presented by hypertensive subjects (90 and 65 kDa).
The 190 kDa isoform would correspond to somatic ACE
and both 90 and 65 kDa would be N-terminal fragments.
Animal studies performed in our laboratory have also shown
that 90 kDa ACE could be a possible genetic marker of
hypertension in different rat strains (11).
Several studies have shown that impaired endothe-
lium-dependent vasodilation is probably genetically pre-
determined, which is a primary phenomenon not directly
related to blood pressure levels (12-14). The events pre-
ceding the development of high blood pressure involve
very subtle and progressive endothelial changes that may
jeopardize baseline production as well as NO release
under stimuli (15).
Based on available data from the literature that consis-
tently show an impairment of endothelial response in normo-
tensive offspring of subjects with EH and also based on our
previous data that have suggested urinary 90 kDa ACE as a
possible marker for hypertension, we evaluated the profile of
ACE isoforms in urine of normotensive subjects with and
without a family history of EH. Our objective was to assess
whether these isoforms could be used as an indicator of
different patterns of endothelial response assessed by high
resolution ultrasound in young normotensive subjects.
Subjects and Methods
Subjects
Healthy male subjects, aged 18 to 40 years old, were
initially divided into two groups according to the presence
(FHH+, N = 35) or absence (FHH-, N = 20) of a family
history of essential hypertension (FHH) from first-degree
relatives. Hypertension was defined as blood pressure
levels equal to or greater than 140 mmHg systolic and/or
90 mmHg diastolic and/or ongoing pharmacological treat-
ment for hypertension. Women were not included in this
study due to the protective effect of estrogen on vascular
reactivity. The protocol of this cross-sectional study was
approved by the Ethics Committee on Human Research of
the Federal University of São Paulo (#095/02). All subjects
received a full explanation of the study protocol and pur-
poses and gave written informed consent.
None of the subjects had any significant past medical
history nor were they receiving any prescribed medication
or vitamins. There was also no previous history of tobacco
use. Subjects underwent a physical examination consist-
ing of weight and height measurements to determine body
mass index, measurement of waist and hips and calcula-
tion of their ratio. Following a 5-min rest, heart rate and
blood pressure were measured in the arm in a seated
position recording the higher blood pressure level at inter-
vals of 1 min for 3 min. The mean blood pressure was used
for further analyses. Biochemical blood profile was deter-
mined from fasting serum samples. Subjects with a labora-
tory abnormality were excluded from this study. The sub-
jects were subsequently scheduled for a brachial artery
reactive test in order to evaluate flow-mediated dilation
(FMD) in response to reactive hyperemia.
Endothelial function assessment
Brachial artery-mode ultrasound. The endothelial func-
tion test was performed by high-resolution B-mode ultra-
sound images using a non-invasive methodology described
by Celermajer et al. (16). The equipment used in this study
was an Ultramark HDI 3000 (Phillips-ATL Ultrasound Inc.,
USA), with a linear transducer of L7-4 MHz. This test
assessed FMD after reactive hyperemia. Diameter and
blood flow velocity were determined in triplicate. The maxi-
mum blood flow (mm/min) was determined in the first 15 s
after cuff release. Ninety seconds after ischemia, 3 meas-
urements of the diameter of the brachial artery were taken
during the diastolic period. This FMD response was re-
ported as the change in percent of end-diastolic diameter
of the brachial artery during reactive hyperemia compared
to the baseline measurement. It was used as a measure of
endothelium-dependent vasodilation.
Purification of ACE
Urine preparation. Urine volume was measured and
the pH was corrected to 8.0 with 1 M Tris buffer. Urine was
centrifuged (3000 rpm). The supernatant was concen-
trated 10X in an Amicon concentrator (USA) and dialyzed
in the same equipment against 50 mM Tris-HCl, pH 8.0,
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containing 150 mM NaCl, with the use of a 30-kDa molec-
ular mass exclusion membrane.
Gel filtration on an AcA-44 column. Individual samples
of the concentrated urine (1.0 mL) were submitted to gel
filtration on an AcA-44 column (1.6 x 84 cm) previously
calibrated with standard proteins (Sigma-Aldrich, USA),
equilibrated with 50 mM Tris-HCl buffer, pH 8.0, containing
150 mM NaCl. Fractions (1.0 mL) were collected at a flow
rate of 20 mL/h. Protein concentration was monitored by
absorbance at 280 nm, and ACE activity was measured
using Hippuryl-His-Leu and Z-Phe-His-Leu as substrates
(17,18). The column was previously calibrated with stand-
ard protein markers.
Protein concentration. Protein concentration was de-
termined by the Bradford method (19) (Bio-Rad Protein
Assay, USA) using bovine albumin as standard.
Immunoblotting. Using 100 µg of total urinary protein,
SDS-PAGE (7.5%) was performed under dissociating con-
ditions with dithiotreitol as described by Laemmli (20).
After the electrophoretic transfer of the proteins from the
polyacrylamide gel to a nitrocellulose membrane
(Immobilon P, Millipore, USA), the nitrocellulose mem-
brane was incubated in 10 mM Tris, pH 8.0, containing 150
mM NaCl, 0.05% Tween 20 and 3 mg/mL bovine serum
albumin, for 90 min followed by incubation for 2 h at room
temperature with antiserum Y4 (Dr. François Alhenc-Gelas,
Unité 367, INSERM, Paris, France) diluted 1:500. The
subsequent steps were carried out using the biotin/strepta-
vidin system (Amersham, USA) as recommended by the
manufacturer.
Statistical analyses
Data were stored at SigmaStat for Windows, version
2.0 (Jandel Corporation, USA). All continuous variables
were examined for normality with the Kolmogorov-Smirnov
test. Data were analyzed by the Student t-test and χ2 test
when applicable, at a significance level of P < 0.05. Values
are reported as means ± standard deviation (SD), unless
otherwise specified. Data analysis was conducted initially
in the subgroups of subjects considering the presence (+)
or absence (-) of a family history of high blood pressure
levels. The next step was based on the presence (+) or
absence (-) of the 90 kDa ACE isoform, irrespective of
FHH, and, finally, we combined the presence of FHH and
the presence of 90 kDa ACE isoform and compared this to
the group in which both conditions were absent.
Results
The presence of ACE found in most FHH+ subjects
was characterized by gel-filtration chromatography in which
three peaks with ACE activity were detected with an esti-
mated molecular mass of 190, 90, and 65 kDa, confirmed
by the expression of the three immunoreactive protein
bands by Western blot analysis as shown in Figure 1. The
same analysis was done for the FHH- subjects who pre-
sented 190 and 65 kDa ACE forms (Figure 1).
Table 1 shows demographic and clinical data from
healthy volunteers based solely on family history of high
blood pressure. Subjects with FHH+ showed a statistically
significant difference in heart rate compared to FHH- (68.5
± 9.2 vs 62.8 ± 8.0, P < 0.05) and a lower total cholesterol
level compared to FHH- (164.4 ± 37.7 vs 186.0 ± 26.3, P <
0.05). We did not find any difference in flow-mediated
dilation between FHH+ and FHH- (12.3 ± 5.6 vs 13.8 ± 6.0,
respectively). Similarly, there was no difference in brachial
artery diameter (4.0 ± 0.5 vs 3.8 ± 0.3 mm).
Subjects with the 90 kDa ACE isoform were compared
to subjects without the 90 kDa ACE isoform (Table 1).
There was a trend towards higher levels of triglycerides
and lower levels in HDL-cholesterol in 90 kDa+ (P = 0.06
for both), and a statistically significant difference in flow-
mediated dilation when the groups were compared (11.7 ±
4.8 vs 15.1 ± 6.7%, 90 kDa+ and 90 kDa-, respectively, P
< 0.05). No differences in brachial artery diameter were
detected (3.9 ± 0.4 vs 4.0 ± 0.5 mm).
The final analysis consisted of a comparison between
subjects with 90 kDa ACE and FHH+ (FHH+/90+) or the
absence of both (FHH-/90-; Table 1). In this analysis, we
observed a statiscally significant difference with lower
levels in HDL-cholesterol in FHH+/90+ (1.27 ± 0.32 vs 1.55
± 0.36, P < 0.05) and higher triglyceride levels (1.24 ± 0.69
vs 0.92 ± 0.21, P < 0.05).
The FHH+/90+ group showed a significant difference
in FMD compared to the FHH-/90- group (12.1 ± 5.0 vs
16.1 ± 6.0%, P < 0.05) indicating a reduction of 24.8% in
FMD in the former group. There were no differences in
brachial artery diameters between groups (3.9 ± 0.4 vs 3.9
± 0.3 mm).
Since our data showed a consistent decrease in FMD
in the presence of FHH and 90 kDa ACE isoform, we
performed a χ2 test to assess the association of these
findings. There were 28 (50.9%) subjects with both condi-
tions, 8 (14.5%) subjects with 90 kDa ACE isoform without
FHH, 7 (12.7%) subjects with FHH and without 90 kDa
ACE isoform, and 12 (21.8%) subjects who did not have
either of these conditions. Our data showed that the pro-
portion of observations in the different categories was
significantly different confirming the association of FHH
and the presence of urinary 90 kDa ACE (P = 0.003).
In order to test which variables could influence endo-
thelial response to reactive hyperemia, we used a stepwise
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Figure 1. Gel filtration and SDS-PAGE of human urine from a normotensive subject without a family history of hypertension (FHH-; A)
and a normotensive subject with a family history of hypertension (FHH+; B). Concentrated urine (1.0 mL) was submitted to gel filtration
on an AcA-44 column, equilibrated, and eluted as described in the Methods section. Fractions of 1.0 mL were collected at a flow rate
of 20 mL/h. Absorbance at 280 nm is indicated by the thin line and ACE activity on Z-Phe-His-Leu by the thick line with black circles.
Western blot analysis of urine was carried out with the Y4 polyclonal anti-ACE antibody. C, Different normotensive FHH- subjects
(lanes 1, 2, and 3 ). D, Different normotensive FHH+ subjects (lanes 1, 2, and 3 ). Arrows indicate bands recognized by the antibody
and the positions of the standards (S, Rainbow molecular weight markers, from 250 to 10 kDa).
Table 1. Clinical features of subjects in groups with or without a family history of hypertension (FHH+ and FHH-), with or without
urinary 90 kDa ACE isoforms (90 kDa+ and 90 kDa-), and with both FHH and urinary 90 kDa ACE isoforms (FHH+/90+) or without both
(FHH-/90-).
Characteristics FHH+ FHH- 90 kDa+ 90 kDa– FHH+/90+ FHH-/90-
(N = 35) (N = 20) (N = 36) (N = 19) (N = 28) (N = 12)
Age (years) 28.5 ± 5.5 27.2 ± 6.8 28.5 ± 5.9 27.2 ± 6.1 29.0 ± 5.8 27.5 ± 7.4
BMI (kg/m2) 24.8 ± 2.9 24.8 ± 3.3 24.8 ± 3.0 24.9 ± 3.1 25.1 ± 3.0 25.8 ± 3.3
WHR 0.87 ± 0.47 0.87 ± 0.05 0.87 ± 0.04 0.87 ± 0.06 0.87 ± 0.05 0.88 ± 0.06
Systolic BP (mmHg) 111.5 ± 7.6 112.3 ± 6.6 111.1 ± 6.9 113.0 ± 7.8 111.6 ± 7.3 114.3 ± 6.7
Diastolic BP (mmHg) 74.5 ± 7.1 75.8 ± 5.3 75.4 ± 5.7 74.0 ± 7.8 74.9 ± 6.0 74.8 ± 6.0
Heart rate (bpm) 68.5 ± 9.2 62.8 ± 8.0* 67.1 ± 9.2 65.5 ± 9.2 68.4 ± 9.8 63.2 ± 10.3
Creatinine (µM) 97.24 ± 8.0 97.24 ± 7.1 97.24 ± 7.07 97.24 ± 7.07 97.2 ± 7.07 97.2 ± 7.07
Glucose (mM) 4.3 ± 0.42 4.24 ± 0.34 4.25 ± 0.4 4.28 ± 0.38 4.21 ± 0.4 4.14 ± 0.3
Total cholesterol (mM) 4.25 ± 0.97 4.8 ± 0.68* 4.41 ± 0.96 4.52 ± 0.83 4.31 ± 1.0 4.82 ± 0.66
HDL-C (mM) 12.67 ± 0.32 13.86 ± 0.37 1.24 ± 0.31 1.43 ± 0.38 1.27 ± 0.32 1.55 ± 0.36+
LDL-C (mM) 2.49 ± 0.83 2.75 ± 1.02 2.63 ± 0.79 2.51 ± 1.12 2.55 ± 0.85 2.66 ± 1.28
Triglycerides (mM) 1.22 ± 0.7 1.2 ± 0.69 1.33 ± 0.75 1.0 ± 0.5 1.24 ± 0.69 0.92 ± 0.21+
Data are reported as means ± SD for N subjects in each group. BMI = body mass index; WHR = waist-hip ratio; BP = blood pressure.
*P < 0.05 vs FHH+; +P < 0.05 vs FHH+ /90+ (Student t-test).
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regression model entering FMD as a dependent variable
and age, history of hypertension, 90 kDa isoform, systolic
blood pressure and diastolic blood pressure as independ-
ent variables. This analysis showed that 90 kDa ACE
isoform (ß = -3.452; SD = 1.596; P = 0.035) was the
independent determinant factor affecting vascular func-
tion, indicating that the presence of this isoform is associ-
ated with a decrease in 3.5% of the vascular dilatation
capacity in this population.
Discussion
The main objective of the present study was to deter-
mine if there is an association between endothelial re-
sponse triggered by reactive hyperemia and the presence
of urinary 90 kDa ACE. Because we were not expecting a
change in smooth muscle cell response to exogenous
nitrate donors in this population, we did not evaluate ni-
trate-mediated dilation as proposed by the Celermajer
method and used by Li et al. (16,21). At this time, there are
no data in the literature describing any other urinary protein
that may represent a marker for hypertension or athero-
sclerotic processes.
There are several inflammatory markers such as C-
reactive protein, von Willebrand factor, vascular cell adhe-
sion molecule, intercellular adhesion molecule, among
others that have been linked to a blunted FMD even in
normotensive subjects with a family history of essential
hypertension (22).
Our data have some limitations due to the small num-
ber of subjects studied, which may be responsible for the
lack of statistical significance in some analyses, especially
those related to FMD. However, we showed a decrease of
24.8% in FMD in the FHH+ group compared with FHH-.
Millgard et al. (23) also failed to demonstrate a significant
difference between normotensive subjects with and with-
out a family history of hypertension regarding forearm
blood flow induced by methacholine. They studied a simi-
lar number of subjects. Another possible explanation re-
fers to the age of our subjects. As extensively described in
the literature (22), aging is an important factor related to
decreasing NO release. Since most of our subjects were
less than 40 years old we did not expect to obtain a more
significant impairment in FMD because we consider this
change to be age-related. In fact, we did not find any
correlation between age and maximal dilation in any sub-
group analysis by Pearson correlation when we took the
presence of EH, or 90 kDa ACE or both into account.
In the second subgroup analysis, when we considered
the presence of 90 kDa ACE irrespective of family history,
although there was a lack of a statistical significance, there
was also a trend in lipid profile indicating a role for hyper-
tension not as a marker but possibly more importantly as
an indicator of an early atherosclerotic process. Indeed,
we detected a significant difference in triglyceride levels in
the presence of 90 kDa ACE, and the endothelial dysfunc-
tion was very similar to that seen in the initial analysis, i.e.,
a 21% reduction in FMD.
When we pooled conditions, family history and 90 kDa
ACE these conclusions were reinforced. We not only de-
tected a significant impairment in FMD (31%) but also
lower levels of HDL-cholesterol, which has a protective
lipoprotein, and higher levels of triglycerides. However,
some of our findings are components of a metabolic syn-
drome, which is considered by some investigators to be
relevant for endothelial dysfunction itself (24,25).
Thus, our data indicate a reduction in vasodilating
effect when subjects presented a family history of high
blood pressure levels, a deleterious lipid profile and uri-
nary 90 kDa ACE. Whether this urinary isoform is a reliable
genetic marker needs further evaluation with larger num-
bers of subjects.
We are starting two new studies in different popula-
tions. The first one aims to confirm the presence of this
isoform in normal volunteers with a family history of pri-
mary hypercholesterolemia and the second study is planned
to be a prospective study on a large population (1150
volunteers) to evaluate the prevalence and incidence of
this 90 kDa isoform, a genetic marker for hypertension.
This study will be based, at least in part, on the detection of
the 90 kDa ACE in the urine of healthy subjects at risk of
developing disease, particularly hypertension and coro-
nary artery disease. Subjects enrolled in this second study
are intended to be followed-up for at least 5 years.
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